Octreotide and Insulin Detemir Interaction

Understanding the Octreotide and Insulin Detemir Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Octreotide belongs to the Somatostatin Analog class and Insulin Detemir belongs to the Long-Acting Insulin class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Octreotide can lower blood sugar, which adds to the effect of insulin and makes low blood sugar more likely. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Octreotide has 14 total documented interactions on file in this dataset, and Insulin Detemir has 11. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Monitor your blood sugar closely and ask your doctor if your insulin dose needs to be adjusted. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Octreotide or Insulin Detemir based on a web page, speak with your prescriber or pharmacist before making any change.